Galapagos Awarded Grant to Accelerate Drug Discovery
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos NV has announced that it has been awarded a €837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone & joint disease portfolio.
The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos.
"Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."
The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos.
"Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."
